Pompe Disease (Late-onset) Clinical Trial
Official title:
A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
This is a phase 1/2 open-label, ascending dose, multicenter clinical study to evaluate the safety and efficacy of AT845 in adult (aged ≥ 18 years) subjects, ambulatory or nonambulatory, with Late Onset Pompe Disease (LOPD).
This study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion. Up to 3 nominal dose levels of AT845 are planned to be evaluated in this study. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort received a single dose of 3x10^13 vg/kg of AT845. The second dose cohort will receive a single dose of 6×10^13 vg/kg. The third dose cohort will receive a single dose of 1×10^14 vg/kg. Dose escalation between cohorts will be based on evaluations of safety and in consultation with the independent DMC. There will be a core observation period of 48 weeks with scheduled visits and assessments. Following the conclusion of the core observation period, subjects will be seen every 6 months for a safety follow-up visit for up to 5 years postdose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00158600 -
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04093349 -
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
|
Phase 1/Phase 2 | |
| Completed |
NCT03285126 -
Pompe Gene Therapy- Screening for Eligibility
|
||
| Recruiting |
NCT05083806 -
MSOT in Pompe Disease
|
N/A | |
| Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
| Active, not recruiting |
NCT03694561 -
Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
|
||
| Completed |
NCT00731081 -
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®
|
N/A | |
| Completed |
NCT00455195 -
Late-Onset Treatment Study Extension Protocol
|
Phase 4 | |
| Recruiting |
NCT05951790 -
Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease
|
N/A | |
| Completed |
NCT01288027 -
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
|
Phase 4 | |
| Recruiting |
NCT00567073 -
Pompe Pregnancy Sub-Registry
|
||
| Completed |
NCT03893240 -
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
|
N/A | |
| Withdrawn |
NCT04094948 -
Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease
|
Phase 2 | |
| Completed |
NCT00250939 -
A Study of rhGAA in Patients With Late-Onset Pompe Disease
|
Phase 2 | |
| Recruiting |
NCT03911505 -
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
|
Phase 3 | |
| Recruiting |
NCT06150820 -
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
|
N/A | |
| Completed |
NCT03729362 -
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
|
Phase 3 | |
| Not yet recruiting |
NCT06178432 -
Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
|
Early Phase 1 | |
| Completed |
NCT00268944 -
Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support
|
Phase 3 | |
| Active, not recruiting |
NCT04138277 -
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD
|
Phase 3 |